Figure 4.
Relation of clinical characteristics to FZR1 and MYC expression levels in 172 B-ALL patients with clinically annotated specimens. (A) Comparison of FZR1 expression levels in B-ALL specimens obtained from patients with newly diagnosed disease who had high levels of MYC expression and either complete remission (CR; n = 69) or no remission (n = 12). The relation between FZR1 expression level and clinical response was evaluated with the Kruskal-Wallis test. (B) Remission duration stratified according to FZR1 expression level in the highly MYC-expressing (MYC-high) B-ALL specimens for the 69 patients in panel A who had complete remission. (C) Overall survival stratified according to FZR1 expression level in the MYC-high B-ALL specimens for the 81 patients in panel A. (D) Survival curves after relapse of B-ALL (68 of the 172 patients) stratified according to the levels of FZR1 and MYC expression in B-ALL specimens obtained at diagnosis.

Relation of clinical characteristics to FZR1 and MYC expression levels in 172 B-ALL patients with clinically annotated specimens. (A) Comparison of FZR1 expression levels in B-ALL specimens obtained from patients with newly diagnosed disease who had high levels of MYC expression and either complete remission (CR; n = 69) or no remission (n = 12). The relation between FZR1 expression level and clinical response was evaluated with the Kruskal-Wallis test. (B) Remission duration stratified according to FZR1 expression level in the highly MYC-expressing (MYC-high) B-ALL specimens for the 69 patients in panel A who had complete remission. (C) Overall survival stratified according to FZR1 expression level in the MYC-high B-ALL specimens for the 81 patients in panel A. (D) Survival curves after relapse of B-ALL (68 of the 172 patients) stratified according to the levels of FZR1 and MYC expression in B-ALL specimens obtained at diagnosis.

Close Modal

or Create an Account

Close Modal
Close Modal